FIELD: biotechnology.
SUBSTANCE: what is presented is using a pharmaceutical composition containing an isolated CD40L binding antibody for treating a patient having a CD40L associated disease.
EFFECT: invention provides introduction of improved anti-CD40L antibodies that do not cause thrombocyte activation or aggregation, but are stable.
6 cl, 25 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD40L-SPECIFIC FRAMEWORK STRUCTURES DERIVED FROM Tn3, AND METHODS OF USE THEREOF | 2012 |
|
RU2826189C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| CSF1R-BASED CHIMERIC PROTEINS | 2018 |
|
RU2792239C2 |
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
| ANTIBODIES TO CD40 AND THEIR APPLICATION METHODS | 2017 |
|
RU2752049C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2779128C2 |
| NEW MODIFIED IMMUNOGLOBULIN Fc-FRAGMENT FUNCTION PROTEIN AND ITS USE | 2020 |
|
RU2800919C2 |
| ANTIBODY SPECIFICALLY BINDING TO ICAM-1 AND ITS USE | 2019 |
|
RU2789757C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
